SENESTECH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 (Exact name of registrant as specified in its charter) | Delaware | 20-2079805 | | --- | --- | ...

SenesTech, Inc. (NASDAQ:SNES) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Robert Blum - Managing Partner-Lytham Partners Ken Siegel - Chief Executive Officer Joel Fruendt - Incoming Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Amit Dayal - H.C. Wainwright Operator Good day, and welcome to the SenesTech Incorporated Reports Third Quarter of 2022 Financial Results Conference Call. All participants will be in a listen-only ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 (State or other jurisdic ...

SenesTech, Inc. (NASDAQ:SNES) Q2 2022 Earnings Confernece Call August 11, 2022 5:00 PM ET Company Participants Robert Blum – Managing Partner-Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Tucker Andersen – Above All Advisors Good afternoon, and welcome to the SenesTech Inc. Reports Second Quarter of Fiscal Year 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After toda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 (I.R.S. Employer (State ...

SenesTech, Inc. (NASDAQ:SNES) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Robert Blum – Managing Partner-Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Tucker Andersen – Above All Advisors Operator Good afternoon, and welcome to the SenesTech Reports First Quarter Fiscal Year 2022 Financial Results. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, t ...

SenesTech, Inc. (NASDAQ:SNES) Q4 2021 Earnings Conference Call March 29, 2022 5:00 PM ET Company Participants Robert Blum - Managing Partner-Lytham Partners Kenneth Siegel - Chief Executive Officer, Director Tom Chesterman - Chief Financial Officer Conference Call Participants Sameer Joshi - H.C. Wainwright Avi Fisher - Long Cast Advisors Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you ...

Part I [Business](index=6&type=section&id=Item%201%2E%20Business) SenesTech commercializes proprietary fertility control technology for animal pest management, initially targeting rats with its non-lethal ContraPest bait - The company's core technology is a proprietary method for managing animal pest populations through fertility control, with the initial focus on **rats**[19](index=19&type=chunk) - ContraPest, the company's first commercial product, is a liquid bait that targets the reproductive systems of both male and female rats, offering a **non-lethal alternative** to traditional rodenticides[22](index=22&type=chunk)[23](index=23&type=chunk) - ContraPest has received unconditional registration from the U.S. Environmental Protection Agency (EPA) as a general-use pesticide and is registered in **all 50 states** and the District of Columbia[24](index=24&type=chunk)[61](index=61&type=chunk) - The company's marketing strategy targets key segments like agribusiness, municipalities, government agencies, and commercial accounts through **direct sales, distributors, and e-Commerce**[42](index=42&type=chunk)[43](index=43&type=chunk) - SenesTech's intellectual property portfolio includes **nine international patent filings** for the ContraPest compound, patent applications for a novel bait station, and an exclusive license with the University of Arizona for future product development[68](index=68&type=chunk)[69](index=69&type=chunk) [Risk Factors](index=14&type=section&id=Item%201A%2E%20Risk%20Factors) The company faces significant risks related to its sole product's commercialization, regulatory hurdles, supply chain, and ongoing financial viability - The company's success is highly dependent on the successful commercialization of **ContraPest**, its only product available for sale[76](index=76&type=chunk) - The COVID-19 pandemic has adversely affected business by restricting travel for sales and field studies, potentially disrupting manufacturing, and causing supply chain issues for raw materials sourced from Asia[75](index=75&type=chunk) - The company has incurred significant operating losses since inception, with a **net loss of $8.3 million in 2021** and an accumulated deficit of **$112.5 million**, raising substantial doubt about its ability to continue as a going concern[128](index=128&type=chunk)[132](index=132&type=chunk) - There is a significant risk related to the supply chain, as the company relies on a **single supplier** for the critical ingredient triptolide, which is sourced from China and other Asian countries[107](index=107&type=chunk)[108](index=108&type=chunk) - The company's common stock is at risk of being delisted from The Nasdaq Capital Market for failing to meet the **minimum bid price requirement of $1.00 per share**[146](index=146&type=chunk) [Properties](index=35&type=section&id=Item%202%2E%20Properties) As of December 31, 2021, SenesTech leases two facilities in Phoenix, Arizona, for its corporate headquarters and manufacturing, with both leases expiring in November 2024 - The company leases two facilities in Phoenix, Arizona: a **5,529 sq. ft. corporate headquarters** and a **5,105 sq. ft. manufacturing facility**[154](index=154&type=chunk) - Both the headquarters and manufacturing facility leases expire on **November 30, 2024**[154](index=154&type=chunk) [Legal Proceedings](index=35&type=section&id=Item%203%2E%20Legal%20Proceedings) The company is involved in a lawsuit filed by a former general counsel seeking over $500,000 for alleged breach of contract related to stock options - A former general counsel, Kennan E. Kaedar, has sued the company for breach of contract related to stock options, seeking **over $500,000 in damages**[406](index=406&type=chunk) - The company denies the allegations, intends to defend itself aggressively, and does not expect the litigation to have a **material impact** on its operations[406](index=406&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=36&type=section&id=Item%205%2E%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) SenesTech's common stock trades on Nasdaq, and the company has never paid cash dividends, intending to retain earnings for operations and growth - The company's common stock trades on the Nasdaq Capital Market under the symbol **"SNES"**[158](index=158&type=chunk) - The company has never declared or paid cash dividends and does not plan to in the foreseeable future[160](index=160&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=Item%207%2E%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) SenesTech continues to incur significant operating losses, with increased revenue in 2021 offset by rising expenses, necessitating additional capital for future operations Financial Performance Summary (2021 vs. 2020) | Metric | 2021 (in thousands) | 2020 (in thousands) | Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $600 | $282 | +112.8% | | **Gross Profit** | $244 | $1 | +24300% | | **Total Operating Expenses** | $9,178 | $7,934 | +15.7% | | **Net Operating Loss** | ($8,934) | ($7,933) | +12.6% | | **Net Loss** | ($8,268) | ($7,937) | +4.2% | | **Net Loss per Share** | ($0.74) | ($2.78) | N/A | - Sales increased by **$318,000 (123%)** in 2021 compared to 2020, attributed to internet sales initiatives and strategic partnerships, though growth was tempered by the COVID-19 pandemic[190](index=190&type=chunk) - Gross profit margin improved significantly to **42.4% in 2021** from less than 1% in 2020, primarily due to increased sales and a $119,000 reserve for obsolete inventory recorded in 2020[192](index=192&type=chunk) - Research and Development expenses increased by **$460,000** in 2021, driven by higher personnel costs, professional fees, and expenses for field and regulatory studies[193](index=193&type=chunk) - Selling, General and Administrative expenses rose by **$784,000** in 2021, mainly due to higher salary and incentive compensation costs, and increased marketing expenses for rebranding and online programs[198](index=198&type=chunk) - The company received full forgiveness of its **$645,700 Paycheck Protection Program (PPP) loan** in June 2021, which was recorded as other income[168](index=168&type=chunk)[204](index=204&type=chunk) - The company expects that its cash on hand of **$9.3 million** as of Dec 31, 2021, will be sufficient to fund operations for at least the next 12 months, but acknowledges the need for additional financing to achieve profitability[209](index=209&type=chunk) [Financial Statements and Supplementary Data](index=50&type=section&id=Item%208%2E%20Financial%20Statements%20and%20Supplementary%20Data) Audited financial statements for 2021 show increased assets and decreased liabilities, but the auditor's "going concern" qualification highlights ongoing net losses and capital deficiency - The independent auditor's report expresses substantial doubt about the company's ability to continue as a going concern due to its history of **net losses** and **net capital deficiency**[237](index=237&type=chunk)[242](index=242&type=chunk) Consolidated Balance Sheet Data (as of Dec 31) | Account | 2021 (in thousands) | 2020 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash | $9,326 | $3,643 | | Total Current Assets | $10,656 | $4,819 | | **Total Assets** | **$11,501** | **$6,022** | | **Liabilities & Equity** | | | | Total Current Liabilities | $943 | $794 | | Total Liabilities | $1,466 | $2,138 | | Total Stockholders' Equity | $10,035 | $3,884 | | **Total Liabilities & Stockholders' Equity** | **$11,501** | **$6,022** | Consolidated Statement of Operations Data (Year Ended Dec 31) | Account | 2021 (in thousands) | 2020 (in thousands) | | :--- | :--- | :--- | | Total Revenue | $600 | $282 | | Gross Profit | $244 | $1 | | Total Operating Expenses | $9,178 | $7,934 | | Net Operating Loss | ($8,934) | ($7,933) | | Net Loss | ($8,268) | ($7,937) | | Net Loss Attributable to Common Shareholders | ($8,268) | ($8,373) | - Net cash used in operating activities was **$7.8 million** in 2021, while net cash provided by financing activities was **$13.6 million**, primarily from the issuance of common stock and warrant exercises[213](index=213&type=chunk)[214](index=214&type=chunk)[217](index=217&type=chunk) - Subsequent to year-end, on March 2, 2022, the company received a notification from Nasdaq for non-compliance with the minimum bid price requirement, giving it until **August 29, 2022**, to regain compliance[418](index=418&type=chunk) [Controls and Procedures](index=86&type=section&id=Item%209A%2E%20Controls%20and%20Procedures) As of December 31, 2021, management concluded that the company's disclosure controls and internal control over financial reporting were effective - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were **effective** as of December 31, 2021[426](index=426&type=chunk) - Management concluded that the company's internal control over financial reporting was **effective** as of December 31, 2021, based on the COSO framework[428](index=428&type=chunk) Part III [Directors, Executive Officers, Corporate Governance, Compensation, and Security Ownership](index=87&type=section&id=Items%2010-14) Information on directors, executive officers, corporate governance, compensation, and security ownership is incorporated by reference from the 2022 Proxy Statement - Information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accounting fees is incorporated by reference from the definitive Proxy Statement for the **2022 Annual Meeting of Stockholders**[434](index=434&type=chunk)[435](index=435&type=chunk)[436](index=436&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=88&type=section&id=Item%2015%2E%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all exhibits filed with the Form 10-K, including corporate documents, forms of securities, material contracts, and certifications - This section provides an index of all exhibits filed with the Form 10-K, including corporate documents, forms of warrants, material contracts, and required certifications[441](index=441&type=chunk)[443](index=443&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | Delaware | 20-2079805 | | --- | --- | ...

SenesTech, Inc. (NASDAQ:SNES) Q3 2021 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Robert Blum – Managing Partner-Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Avi Fisher – Long Cast Advisors George Park – Private Investor Operator Good day, and welcome to the SenesTech Third Quarter Fiscal Year 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructio ...